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Abstract
Background: Intestinal microbiota operated as a whole and was closely related with human health. Previous
studies had suggested close relationship between liver cirrhosis (LC) and gut microbiota.
Methods: To determine the functional characteristic of the intestinal microbiota specific for liver cirrhosis, the fecal
metaproteome of three LC patients with Child-Turcotte-Pugh (CTP) score of A, B, and C, and their spouse were first
compared using high-throughput approach based on denaturing polyacrylamide gel electrophoresis and liquid
chromatography–tandem mass spectrometry in our study.
Results: A total of 5,020 proteins (88 % from bacteria, 12 % form human) were identified and annotated based on
the GO and KEGG classification. Our results indicated that the LC patients possessed a core metaproteome including
119 proteins, among which 14 proteins were enhanced expressed and 7 proteins were unique for LC patients
compared with the normal, which were dominant at the function of carbohydrate metabolism. In addition, LC
patients have unique biosynthesis of branched chain amino acid (BCAA), pantothenate, and CoA, enhanced as
CTP scores increased. Those three substances were all important in a wide array of key and essential biological
roles of life.
Conclusions: We observed a highly comparable cirrhosis-specific metaproteome clustering of fecal microbiota
and provided the first supportive evidence for the presence of a LC-related substantial functional core mainly
involved in carbohydrate, BCAA, pantothenate, and CoA metabolism, suggesting the compensation of intestinal
microbiota for the fragile and innutritious body of cirrhotic patients.
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Background
Human intestinal tract is colonized by a complex and in-
timate microbial community that is maintained from
early to late adulthood [1]. Human intestinal microbiota
was an important organ which has been neglected for a
long time. A lot of evidence has suggested that intestinal
microbiota works as a whole and plays an important role
in human health [2].
Cirrhosis is a condition in which the liver failed to work
properly due to long-term damage. The anatomy and
physiological functions of liver and intestinal microbiota
share a close relationship as a result of enterohepatic
circulation. As the cirrhosis worsen, it was usually ac-
companied with intestinal inflammation, which may
affect the prognosis significantly [3]. Previous studies
had revealed the important influence of gut microbiota
dysbiosis on the complications of advanced liver cirrhosis
(such as spontaneous bacterial peritonitis and hepatic en-
cephalopathy) [4] and on the induction and progress of
liver damage at early cirrhosis (such as alcoholic hepatitis
and nonalcoholic fatty liver disease) [5]. It has been
identified that extensive differences in the microbiota
community and metabolic potential existed in the fecal
microbiota of cirrhotic patients, and the prevalence of
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potentially pathogenic bacteria, such as Enterobacteria-
ceae and Streptococcaceae, with the reduction of beneficial
populations such as Lachnospiraceae in patients with
cirrhosis may affect prognosis [3, 6]. In addition, The
functional diversity was significantly reduced in the fecal
microbiota of cirrhotic patients compared with in the
controls. At the module or pathway levels, the fecal
microbiota of the HBLC patients showed enrichment in
the metabolism of glutathione, branched-chain amino
acid, nitrogen, and lipid, whereas there was a decrease
in the level of aromatic amino acid, bile acid and cell
cycle related metabolism [3]. These high-throughput
analyses lay the groundwork for predicting the protein
potential of the intestinal microbiota. However, the func-
tional and metabolic associations between intestinal micro-
biota and cirrhosis in humans are still lacking.
The rapidly increasing catalogue of proteins from intes-
tinal origin provides a platform for high-throughput func-
tional characterization [7]. In the past 20 years, more and
more interests were focused on fecal microbiota, partly
due to the fast emerging sequencing technique. Given that
proteins are much more actual and stable, proteome-based
analyses can be expected to provide a more accurate and
real view of the functionality of the intestinal microbiota.
The LC-MS/MS method has a higher level of proteome
coverage, and is more efficient and accurate to analyze
differential global protein expression quantitatively and
qualitatively. So far there have been several reports re-
lated with the use of metaproteomics to characterize
complex bacterial ecosystems [8, 9]. 2015, Hernández E
et al. collected intestinal microbiota proteins from two
adult patients receiving 14-days β-lactam therapy, seven
obese and five lean adolescents, followed by metapro-
teome measurements, to assess the functional differences
and metabolic effects in human gastrointestinal tract re-
lated with antibiotic treatment and obesity [10]. 2012,
Pérez-Cobas AE carried out the multi-omic research on
fecal samples from one patient subjected to a β-lactam
intravenous therapy, which suggested that antibiotics may
ultimately alter the energy metabolism balance in human
gastrointestinal tract [11]. 2012, faecal samples were col-
lected from 3 healthy female subjects over a period of six
to twelve months to research the composition and stability
of human intestinal metaproteome [12]. 2006, Klaassens
ES et al. collected fecal samples from two infants at differ-
ent ages to characterize the complex intestinal bacterial
structure, and illustrated the feasibility of metaproteomic
approach in analyzing complex mciroecosystem [13].
In this work, human intestinal microbiota was regarded
as a whole to analyze. A high-throughput LC-MS/MS
measurement were used to detect the metaproteomic
changes in the intestinal microbiota of LC patients.
This is the first culture-independent metaproteomic ana-
lysis in the gastrointestinal tract from cirrhotic patients.
Our findings may provide a more comprehensive under-
standing of fecal microbiota in patients with cirrhosis, and




The Child-Turcotte-Pugh (CTP) scoring system was used
to assess the severity of cirrhosis. Three LC patients (CTP
score of A, B, C) and their corresponding spouse, in the
age range of 50–60 and with a body mass index (BMI) =
18.5–24.9 kg m−2, were enrolled in this study. Cirrhosis
was diagnosed according to the gold standard of biopsy in
all patients. Cases that had other complications (such as
peritonitis or hepatic encephalopathy) were excluded in
this study. All healthy individuals had normal liver bio-
chemistry test results with no evidence of hepatic or
other diseases. None of the subjects had food preferences,
or received antibiotics, probiotics, steroids or other
hormones (including oral, intramuscular or intraven-
ous injection) for at least 3 months before enrolment.
Each object was asked to provide a fresh stool sample,
which were subjected to metaproteome extraction im-
mediately. This study was approved by the Institutional
Review Board of Affiliated Hospital of Academy of
Military Medical Sciences. All participants signed an
informed consent form prior to entering the study.
The study conformed to the ethical guidelines of the
1975 Declaration of Helsinki.
Protein extraction
Faecal samples were resuspended in PBS and vortexed
to homogenize the sample. Proteins were precipitated in
pre-chilled TCA (trichloroacetic acid)-acetone (50 g TCA
dissolved in 500 ml acetone) at -20 °C for 2 h. After
centrifugation at 20,000 × g for 30 min, the protein pellet
was washed with pre-chilled acetone and ultrasonicated in
lysis buffer (8 M urea, 30 mM HEPES (4-(2-Hydroxyethyl)-
1-piperazineethanesulfonic acid), 1 mM PMSF (Phenyl-
methanesulfonyl fluoride), 2 mM EDTA (Ethylene Diamine
Tetraacetie Acid), 10 mM DTT (DL-Dithiothreitol)). After
centrifugation at 20,000 × g for 30 min, the supernatant
were reduced with 10 mM DTT at 56 °C for 1 h, and
alkylated with 55 mM IAM (iodoacetamide) at room
temperature for 1 h in the dark. The treated proteins
were precipitated in pre-chilled acetone at −20 °C for
3 h. After centrifugation at 20,000 × g for 30 min, the
protein pellet was resuspended and ultrasonicated in
pre-cooled 50 % TEAB (tetraethylammonium bromide)
buffer with 0.1 % SDS, and then centrifuged at 20,000 × g
to pellet the undissolved substance. The protein concen-
trations were measured by Bradford assay.
Wei et al. BMC Gastroenterology  (2016) 16:121 Page 2 of 13
1 D gel electrophoresis and in-gel protein digestion
To reduce the complexity of the protein extract, a 1D
gel fractionation according to molecular weight was car-
ried out. Equal volumes of protein solutions were mixed
with 4 × Laemmli buffer and Biorad reducing agent and
run on NuPAGE 4–12 % Bis-Tris gels (Invitrogen) at a
constant voltage of 80 V for 20 min followed by 200 V
for 30 min. Gels were stained with PageBlue (Fermentas).
Gel pieces were washed and proteins reduced, alky-
lated and tryptically digested overnight as described
previously [14].
LC-MS/MS measurements
Peptide samples were analyzed by LC-MS/MS on a
quadrupole-Orbitrap mass spectrometer (Q-Exactive;
Thermo Fisher, Germany) equipped with a 15 cm (length)
by 75 μm (inside diameter) column packed with 5 μm
C18 medium (150A, Thermo Fisher) which was remained
at 21 °C throughout the analysis. Mobile phase A was
MilliQ water with 0.1 % (v/v) formic acid. Mobile phase B
was 99.9 % (v/v) acetonitrile and 0.1 % acetic acid. Gradi-
ent was run from 0 % B to 30 % B over 40 min and then
to 80 % B for 15 min. An electrospray voltage of 1.8 kV
was applied. By data-dependent acquisition, the mass
spectrometer was programmed to acquire tandem mass
spectra from the top 20 ions in the full scan from 350 to
2,000 m/z. Dynamic exclusion was set to 15 s, singly
charged ions were excluded, the isolation width was set to
2 m/z. The full MS resolution was set to 70,000, and the
MS/MS resolution to 17,500. Normalized collision energy
was set to 28, automatic gain control to 1e6, maximum fill
MS to 20 ms, maximum fill MS/MS to 60 ms, and the
under fill ratio to 0.1 %. Each sample was repeated triply.
Protein identificaton
Peptide identification were performed using Mascot v2.3.01
(Matrix Science Ltd.) (http://www.matrixscience.com)
licensed in-house (http://www.proteomics.cn) [15]. Mono-
isotopic peptide masses were used to search the databases,
allowing a peptide mass accuracy of 30 ppm and fragment
ion tolerance of 0.2 Dalton. Both methionine oxidation
and cysteine carboxyamidomethylation were considered
in the process. For protein identification, peptide masses
were searched against the publically available database for
Uniprot-Human database and Uniprot-Bacteria database.
For unambiguous identification of proteins, more than five
peptides must be matched and the sequence coverage
must be greater than 15 %.
Bioinformatic analysis
Microbial proteins which had at least one peptide iden-
tification in each individual were defined. Functional
classification of identified proteins was performed by
BLASTPGP [16] searching against the databases of
Cluster of Orthologous Groups database (COGs,
ftp://ftp.ncbi.nih.gov/pub/COG/COG2014/static/lists/
listCOGs.html) [17]. The COG associated with the
best BLAST hit (≤1E-10 cutoff ) was assigned to the
query protein. The identified COGs were mapped on
the KEGG metabolic pathways and visualized with the
online application of iPath [18]. The spectra those proteins
were identified with were taken to sum on COG level per
all measurements and were used to rank the COGs ac-
cording to spectra number. Sequences which did not hit
any specific COG were subjected to BLAST search against
the NCBI non-redundant database. The cellular localiza-
tions of the proteins were predicted by PSORTb version
3.0 [19]. Prediction of signal peptides was carried out with
SignalP Version 4.1 [20]. The metaproteomic data from
three LC patients (CTP score of A, B, C) were compared
with their corresponding spouse, respectively.
Results
Identification of proteins and metabolic pathways in the
fecal metaproteome
Three LC patients with CTP score of A, B, C (coded as
AP, BP, CP) and their corresponding spouse (coded as
AN, BN, CN) were enrolled in this study. Characteristics
of the subjects were given in Table 1. Unprocessed fecal
material from those subjects were used not only to
Table 1 Characteristics of the patients and controls
Terms AP AN BP BN CP CN
Age 52 50 59 56 51 50
Gender Male Female Male Female Male Female
BMI index 24.1 24.3 25.3 25.1 24.9 25.0
Total bilirubin (μmol/L) 6.6 — 11.8 — 36.3 —
Albumin (g/L) 37.1 — 30.5 — 26.2 —
Stage of hepatic encephalopathy 0 — 0 — 1 —
Ascites degree No — Moderate — Severe —
Prothrombin time prolonged (seconds) 0 — 2 — 2.1 —
CTP A — B — C —
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reappear the intestinal microbial proteome characteris-
tics, but also to allow detection of human proteins. Fecal
metaproteome were extracted and subjected to 1D-gel
(Fig. 1a). A total of over 100,000 spectra were generated
by the collection of LC-MS/MS. The raw data has been
uploaded to the public websites (http://www.iprox.org/
my/index, user ID: reviewer 719, password: 6s6kd6lp). In
this study, a total of 5,020 proteins were identified with
two or more peptide identifications, including 4,401 (88 %)
from bacteria proteins and 619 (12 %) from human pro-
teins (Fig. 1b). Results from the annotation to Uniprot-
Bacteria database suggested that almost equal and 600
proteins were identified from AP and AN, and 1100 and
1102 proteins identified from BP and CP respectively, al-
most twice more than their controls. Results of the fecal
metaproteome assigned to Uniprot-Human database sug-
gested a relatively stable expression and an average of 100
proteins were identified from each sample (Fig. 1c). Anno-
tation results of bacterial proteins and human proteins
from each sample were shown in Additional file 1:
Table S1 and Additional file 2: Table S2. To retrieve fur-
ther functional information, we annotated these proteins
based on the GO and KEGG classification and the overall
number of proteins identified were shown in Table 2.
Core metaproteome specific for LC patients
To obtain the LC-related common microbial core prote-
ome, we selected proteins that were found in all the three
patients. A total of 119 proteins fulfilled this criterion and
their description and functional characteristics were shown
in Additional file 3: Table S3. The common and core
metaproteome could be grouped into 18 COGs and the
most predominant functional categories were J (transla-
tion), G (carbohydrate transport and metabolism), C
(energy production and conversion), F (nucleotide trans-
port and metabolism), and E (amino acid transport and
metabolism) (Fig. 2). Nearly 19 % proteins could be
assigned to carbohydrate transport and metabolism, and
8 % assigned to amino acid transport and metabolism,
reflecting the high metabolic activity of the intestinal
microbiota from LC patients. Among those 119 core
proteins, 14 proteins enhanced their expression levels
and 7 proteins were specific for LC patients compared
with the normal, which were described as below.
Differential fecal microbial metabolism and proteins in LC
patients
Fourteen KEGG pathway maps were detected to have dif-
ferent metabolic capacities in the fecal microbiota between
Fig. 1 Electrophoresis maps and annotation results of the fecal metaproteome from six subjects. a The 1D-gel showing the protein pattern from
fecal metaproteome of six subjects. b Proportion of proteins allocated to uniprot-bacteria and uniprot-human databases. In this study, a total of
5,020 proteins were identified with two or more peptide identifications, in which 88 % from bacteria proteins and 12 % from human proteins.
c Number of proteins allocated to uniprot-bacteria and uniprot-human databases in each sample
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patients and the normal, including eleven pathways
enhanced and three pathways weakened in patients
(Additional file 4: Table S4). In the same metabolic
pathway, different proteins were identified in different
samples, suggesting that the intestinal microbiota have
abundant species diversity and protein complexity. In
five metabolic pathways, we detected same proteins in
different samples, most of which were assigned to carbohy-
drate metabolism. One of the most predominant pathways
was glycolysis/gluconeogenesis, showing high redundancies
among microbiota; all the glycolytic/gluconeogenic en-
zymes could be identified in patients, highlighting the
enhanced material metabolism capacity in intestinal
microbiota of LC patients.
Fourteen proteins were detected to have enhanced ex-
pression level in all the three patients compared with the
normal (Table 3), which could be grouped into four
COGs (J: Translation, G: Carbohydrate transport and
metabolism, E: Amino acid transport and metabolism, O:
Posttranslational modification, protein turnover, chaperones),
suggesting the enhanced material transport and metabolism
function in fecal microbiota from LC patients.
Compatible with the important sugar degradation
potential of the gut microbiota, various proteins in-
volved in carbohydrate transport and metabolism were
identified and enhanced in patients, including transketo-
lase, transaldolase, xylose isomerase, and glyceraldehyde
Table 2 Overall number of proteins identified from patients
and the normal
Uniprot-Bacteria Uniprot-Human
Patients Normal Patients Normal
Total Protein Number 2,819 1,582 314 305
GO (Cellular Component)
Number of GOa 93 81 171 190
Number of Proteinsb 1,213 594 87 98
GO (Biological Process)
Number of GOa 1,004 781 867 1,082
Number of Proteinsb 1,890 954 75 92
GO (Molecular Function)
Number of GOa 861 596 230 248
Number of Proteinsb 2,173 1,092 91 110
KEGG
Number of KEGGa 127 100 106 123
Number of Proteinsb 1,697 865 80 80
aNumber of GO terms or KEGG pathways identified
bNumber of proteins identified and assigned to corresponding GO terms or
KEGG pathways
Fig. 2 Functional category of the common and core metaproteome from LC patients. The common and core metaproteome could be grouped
into 19 COGs and the most predominant functional categories were J, G, C, F, and E. Categories were taken from the TIGR-CMR (www.tigr.org)
and the abbreviation was used to mark the categories. J, translation; K, transcription; L, replication, recombination, and repair; D, cell cycle control,
mitosis, and meiosis; V, defense mechanisms; M, cell wall/membrane biogenesis; U, intracellular trafficking and secretion; O, post-translational
modification, protein turnover, chaperones; C, energy production and conversion; G, carbohydrate transport and metabolism; E, amino acid
transport and metabolism; F, nucleotide transport and metabolism; H, coenzyme transport and metabolism; I, lipid transport and metabolism;
P, inorganic ion transport and metabolism; Q, secondary metabolite biosynthesis, transport, and catabolism; R, general function prediction
only; S, function unknown; —, not in Clusters of Orthologous Groups (COG)
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Table 3 Characteristics of proteins with enhanced expression level in the fecal microbiota from LC patients or specific for patients’ intestinal microbiota compared with the
normal
No. Description Gene name Length MW [Da] KO COG Subcellular location Signal peptide prediction GO Functonal Categorya
Proteins with enhanced expression level in the fecal microbiota from LC patients

























































































11 ABC transporter substrate-binding protein BBPC_1795 430 47,488 K10117 COG1653 Cytoplasmic Absence GO:0006810
GO:0005215
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Table 3 Characteristics of proteins with enhanced expression level in the fecal microbiota from LC patients or specific for patients’ intestinal microbiota compared with the
normal (Continued)
Proteins specific for patients’ intestinal microbiota compared with the normal



























































Table 3 Characteristics of proteins with enhanced expression level in the fecal microbiota from LC patients or specific for patients’ intestinal microbiota compared with the
normal (Continued)

















aCategories were taken from the TIGR-CMR (www.tigr.org) and the abbreviation was used to mark the categories. J Translation, O Posttranslational modification, protein turnover, chaperones, G Carbohydrate transport












3-phosphate dehydrogenase, which were grouped into
the KEGG pathway of map 00030 (Pentose phosphate
pathway), map 00040 (Pentose and glucuronate intercon-
versions), map 00051 (Fructose and mannose metabol-
ism), map 00010 (Glycolysis/Gluconeogenesis), as well as
map 01110 (Biosynthesis of secondary metabolites). The
abundance of bacterial proteins devoted to the utilization
of carbohydrates testified for their importance as meta-
bolic substrates in the intestinal tract.
The most significantly differential protein was glyceral-
dehyde 3-phosphate dehydrogenase (EC1.2.1.12), which
catalyzes the oxidative phosphorylation of glyceraldehyde
3-phosphate (G3P) to 1,3-bisphosphoglycerate (BPG) using
the cofactor NAD. This protein is involved in step 1 of
the subpathway, part of carbohydrate degradation and
glycolysis pathway, that synthesizes pyruvate from D-
glyceraldehyde 3-phosphate. 3-phosphoglycerate kinase
assists in the transformation of 3-phospho-D-glycerate
to 3phospho-D-glyceroyl phosphate by consumption of
ATP.
Another significantly differential protein was glutamate
dehydrogenase (GDH). Moreover, detailed analysis of
these peptides revealed GDH to show a high level of re-
dundancy in the intestinal tract since we could identify it
as a major protein in a large variety of bacterial families,
including Bacteroidaceae, Streptococcaceae, Ruminococca-
ceae and Bifidobacteriaceae (Additional file 1: Table S1).
It is known that GDH not only links the nitrogen and
the carbon-cycle via the incorporation of ammonia into
2-ketoglutarate, but also have another metabolic role
and act as an electron sink [12]. This pathway, which
operates in several strict anaerobes to assure a low level
of free electrons, resulting in the net conversion of
pyruvate and ammonia into alanine while consuming
NAD(P)H that can be generated via a ferredoxin NAPDH
oxidoreductase [12]. This potential role of intestinal GDH
as an electron sink requires the activity of aminotransfer-
ases, many of which were identified in the metaproteome,
including branched-chain amino acid aminotransfer-
ase, aminotransferase class-V family protein, phospho-
serine aminotransferase, taurine–pyruvate aminotransferase,
aspartate/tyrosine/aromatic aminotransferase, glucosamine–
fructose-6-phosphate aminotransferase, acetylornithine ami-
notransferase, N-succinyldiaminopimelate aminotransferase,
histidinol-phosphate aminotransferase, 4-aminobutyrate
aminotransferase, which were all specially enhanced in
BP and CP patients.
Unique fecal microbial proteins and metabolism for LC
patients
To identify the fecal microbiota proteins specific for
patients, we selected proteins that were found only in
all the three patients but absent in the normal. A total
of seven proteins fulfill the criterion. Charicteristics of
unique fecal microbial proteins for LC patients were
shown in Table 3.
Additionally, Two KEGG pathways, map 00290 (Valine,
leucine and isoleucine biosynthesis) and map 00770
(Pantothenate and CoA biosynthesis) were common in
the fecal microbiota from the three patients and absent
in normal. As the patients’ condition worse, the number
of specific enzymes from the two metabolic pathways
were remarkably increased, and the metabolic pathways
were enhanced. In patient CP, the specific enzymes from
map 00290 and map 00770 were almost covered the
whole metabolic pathway (Fig. 3). LC patients have an en-
hanced function of branched-chain amino acid (BCAA)
and vitamin metabolism, which were in accordance with
the metagenomic results from Wei [21].
The most unique enzymes detected were ketol-acid
reductoisomerase (EC 1.1.1.86) and dihydroxy-acid dehy-
dratase (EC 4.2.1.9). Degradation of BCAA involved the
branched-chain alpha-keto acid dehydrogenase complex.
Those two enzymes were both important in the KEGG
pathways of map 00290 and map 00770 and have the pro-
tein interactions of neighborhood and coexpression.
Ketol-acid reductoisomerase (EC 1.1.1.86), specific in
fecal microbiota from patients, were key enzyme from
metabolic pathway of valine, leucine and isoleucine bio-
synthesis and pantothenate and CoA biosynthesis. This
enzyme can catalyse the reduction of 2-ethyl-2-hydroxy-
3-oxobutanoate to 2,3-dihydroxy-3-methylpentanoate. This
protein is involved in step 2 of the subpathway that
synthesizes L-valine from pyruvate and L-isoleucine
from 2-oxobutanoate, which are part of the pathway of
L-valine biosynthesis and L-isoleucine biosynthesis, re-
spectively. The chemical reactions and pathways resulting
in the formation of valine, 2-amino-3-methylbutanoic
acid and isoleucine, (2R*, 3R*)-2-amino-3-methylpentanoic
acid. In addition, this enzyme is involved in step 2 of the
subpathway that synthesizes patothenate from pyruvate,
which are part of the pathway of Pantothenate and CoA
biosynthesis.
Dihydroxy-acid dehydratase (EC 4.2.1.9), specific in the
fecal microbiota from BP and CP, catalyzes third step in
the common pathway leading to biosynthesis of branched-
chain amino acids and is important in the KEGG pathway
of map 00290 and map 00770. This protein is involved in
step 3 of the subpathway that synthesizes L-isoleucine
from 2-oxobutanoate and L-valine from pyruvate, which
are part of the pathway of L-valine biosynthesis and
L-isoleucine biosynthesis, respectively.
Branched-chain-amino-acid transaminase (EC 2.6.1.42),
specific in the fecal microbiota from BP and CP, belongs
to the class-IV pyridoxal-phosphate-dependent amino-
transferase family. Branched-chain-amino-acid transamin-
ase can catalyze the transfer of an alpha-amino group
from an amino acid to an alpha-keto acid leading to
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biosynthesis of branched-chain amino acids and is import-
ant in the KEGG pathway of map 00290 and map 00770.
The amino group is usually covalently bound by the pros-
thetic group pyridoxal phosphate.
Non-bacterial proteins
The vast majority of the identified proteins, approximately
87.7 %, were of microbial origin. Moreover, in total, 619
human proteins, excluding possible contaminants [22],
were identified as representing host cell activity along the
digestive tract. In general, the identified human proteins
were mostly involved in carbohydrates and proteins diges-
tion, maintaining mucosal barrier function, and providing
energy resources for intestinal microbes.
Discussion
In any microbiome environment, expression of microbiota
proteins were all closely affected by the microenvironment
and bacteria-host interactions [23]. However, culture-based
research was unable to reappear the real condition of
microbiome in the environment and the insufficient micro-
biome sequence information confounded identification of
the proteins [12]. Currently, people were focusing more
and more interests on metaproteomics approaches to
monitor the disease related functional products of the
microbiota [13], and the ongoing protein library analysis
enabled meaningful identification in time [2, 24]. For the
first time, extraction of metaproteome from LC patients
and tentative identification using LC-MS/MS were carried
out in this study. To retrieve further functional information,
we annotated these proteins based on the GO and KEGG
classification and analyzed the characteristic of the intes-
tinal microbiota from LC patients at the expression level.
As revealed by the protein identification searched against
the publically available database for Uniprot-Bacteria
database, nearly equal proteins were identified from AP
and AN, however, almost twice proteins were identified
from BP and CP compared with the normal, implying
that as the disease processed, the changes in intestinal
microenvironment caused by cirrhosis compelled fecal
microbiota to enhance their growth activity and protein
expression to survival.
A LC-related core metapoteome including 119 proteins
was described in this study. Majority of the proteins could
Fig. 3 Specific expressed proteins for LC patients allocated to the KEGG pathway of map 00290 (a) and map 00770 (b). Proteins specific expressed for
LC patients were highlighted. As the patients’ condition worse, the number of specific enzymes from the two metabolic pathways were remarkably
increased, and the metabolic pathways were enhanced. In patient CP, the specific enzymes from map 00290 and map 00770 were almost covered the
whole metabolic pathway
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be assigned to carbohydrate and amino acid transport and
metabolism, reflecting the active metabolic ability of the
intestinal microbiota from LC patients. Among those 119
core proteins, 14 proteins, involved in carbohydrate trans-
port and metabolism, enhanced their expression levels in
the fecal microbiota from LC patients, which further illus-
trated that human gut bacteria encountered a broad
spectrum of carbohydrate substrates.
Fourteen KEGG pathway maps were detected to have
different metabolic capacities in the fecal microbiota
between patients and the normal, including eleven path-
ways enhanced and three pathways weakened in patients.
In the same metabolic pathway, different proteins were
identified in different samples, suggesting the abundant
species diversity and protein complexcity, that is why we
got rid of species boundaries and regarded fecal micro-
biota as a whole in this study.
Seven proteins were identified as the unique fecal micro-
bial proteins for LC patients compared with the normal.
Correspondingly, two KEGG pathways, map 00290 (Valine,
leucine and isoleucine biosynthesis) and map 00770
(Pantothenate and CoA biosynthesis), were unique in
the fecal microbiota from LC patients. More interestingly,
as the patients’ condition worse, the patients-specific en-
zymes were almost covered the whole metabolic pathway.
Valine, leucine and isoleucine were all BCAA, which were
among the nine essential amino acids for humans. Panto-
thenate was an essential nutrient for human and used to
synthesize CoA, as well as to synthesize and metabolize
proteins, carbohydrates, and fats. Pantothenate, in the
form of CoA, is also required for acylation and acetylation,
which, for example, are involved in signal transduction
and enzyme activation and deactivation, respectively
[25, 26]. CoA was important in energy metabolism for
pyruvate to enter the TCA cycle as acetyl-CoA, and for
α-ketoglutarate to be transformed to succinyl-CoA in
the cycle, as well as in the biosynthesis of many important
compounds such as fatty acids, cholesterol, and acetylcho-
line [26]. BCAA and pantothenate were both important in
a wide array of key biological roles. LC patients were weak
fitness and as a result the peripheral tissues need to in-
crease their consumption of a variety of nutrients includ-
ing carbohydrates, BCAA and vitamins. The specific
expression of bacterial proteins devoted to map 00290
and map 00770 testified the compensation for the fragile
health and need for nutrition.
Conclusions
Altogether, we observed a first and highly comparable
cirrhosis-specific metaproteome clustering of fecal micro-
biota. Our findings provided a supportive evidence for the
presence of a LC-related substantial metaproteome core
which enhanced the expression level involved in sugar
transport and degradation, as well as BCAA, pantothenate
and CoA biosynthesis. Our results suggested that the
fecal microbiota not only had strong adaptability to the
intestinal microenvironment, but also could compensate
for the fragile and innutritious body of cirrhotic patients.
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